Cargando…

Associations of mRNA:microRNA for the Shared Downstream Molecules of EGFR and Alternative Tyrosine Kinase Receptors in Non-small Cell Lung Cancer

Lung cancer is the top cancer killer worldwide with high mortality rate. Majority belong to non-small cell lung cancers (NSCLCs). The epidermal growth factor receptor (EGFR) has been broadly explored as a drug target for therapy. However, the drug responses are not durable due to the acquired resist...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Fengfeng, Meng, Fei, Wang, Lili, Wong, S. C. Cesar, Cho, William C. S., Chan, Lawrence W. C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2016
Materias:	Genetics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061729/ https://www.ncbi.nlm.nih.gov/pubmed/27790245 http://dx.doi.org/10.3389/fgene.2016.00173

Ejemplares similares

MiR-30a-5p Overexpression May Overcome EGFR-Inhibitor Resistance through Regulating PI3K/AKT Signaling Pathway in Non-small Cell Lung Cancer Cell Lines
por: Meng, Fei, et al.
Publicado: (2016)

Editorial: Role of RNA in Molecular Diagnostics of Cancer
por: Cho, William C. S., et al.
Publicado: (2020)

Variability in organ-specific EGFR mutational spectra in tumour epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors
por: Weber, F, et al.
Publicado: (2005)

MiR-30 Family Potentially Targeting PI3K-SIAH2 Predicted Interaction Network Represents a Novel Putative Theranostic Panel in Non-small Cell Lung Cancer
por: Chan, Lawrence W. C., et al.
Publicado: (2017)

The role of RICTOR downstream of receptor tyrosine kinase in cancers
por: Jebali, Ahlem, et al.
Publicado: (2018)

Tyrosine kinase inhibitor acquired resistance mechanism alternates between EGFR and ALK in a lung adenocarcinoma patient
por: Hu, Yijuan, et al.
Publicado: (2019)

Regulation of the Alternative Neural Transcriptome by ELAV/Hu RNA Binding Proteins
por: Wei, Lu, et al.
Publicado: (2022)

Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis
por: Kuan, Feng-Che, et al.
Publicado: (2015)

Analysis of the lncRNA–miRNA–mRNA Network Reveals a Potential Regulatory Mechanism of EGFR-TKI Resistance in NSCLC
por: Ding, Dandan, et al.
Publicado: (2022)

Identification of Six Prognostic Genes in EGFR–Mutant Lung Adenocarcinoma Using Structure Network Algorithms
por: Zhang, Haomin, et al.
Publicado: (2021)

Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma
por: Mezzapelle, R, et al.
Publicado: (2013)

Activation of the Syk tyrosine kinase is insufficient for downstream signal transduction in B lymphocytes
por: Hsueh, Robert C, et al.
Publicado: (2002)

Receptor tyrosine kinases and schistosome reproduction: new targets for chemotherapy
por: Morel, Marion, et al.
Publicado: (2014)

Modeling Equilibrium of microRNA Expression
por: Chan, Lawrence W. C.
Publicado: (2011)

The Role of Alternative Polyadenylation in the Regulation of Subcellular RNA Localization
por: Arora, Ankita, et al.
Publicado: (2022)

Sorting mRNA Molecules for Cytoplasmic Transport and Localization
por: Neriec, Nathalie, et al.
Publicado: (2018)

Co-expression Pattern Analysis of miR-17-92 Target Genes in Chronic Myelogenous Leukemia
por: Wang, Fengfeng, et al.
Publicado: (2016)

Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors
por: Ray, Paramita, et al.
Publicado: (2016)

The Crosstalk Between Epigenetic Mechanisms and Alternative RNA Processing Regulation
por: Zhang, Jian, et al.
Publicado: (2020)

Signatures of mRNA Alternative Polyadenylation in Arabidopsis Leaf Development
por: Yu, Zhibo, et al.
Publicado: (2022)

Re-evaluating the impact of alternative RNA splicing on proteomic diversity
por: Manuel, Jeru Manoj, et al.
Publicado: (2023)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
por: Huang, Lihua, et al.
Publicado: (2015)

Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC
por: Kobayashi, Keigo, et al.
Publicado: (2023)

Expression Changes Confirm Genomic Variants Predicted to Result in Allele-Specific, Alternative mRNA Splicing
por: Mucaki, Eliseos J., et al.
Publicado: (2020)

Identification of a Potentially Functional circRNA-miRNA-mRNA Regulatory Network in Melanocytes for Investigating Pathogenesis of Vitiligo
por: Li, Lili, et al.
Publicado: (2021)

Prediction of small molecule drug-miRNA associations based on GNNs and CNNs
por: Niu, Zheyu, et al.
Publicado: (2023)

Non-coding RNA in Fragile X Syndrome and Converging Mechanisms Shared by Related Disorders
por: Zhou, Yafang, et al.
Publicado: (2019)

Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas
por: Bjaanæs, Maria Moksnes, et al.
Publicado: (2014)

Design, Synthesis, and Evaluation of Ribose-Modified Anilinopyrimidine Derivatives as EGFR Tyrosine Kinase Inhibitors
por: Hu, Xiuqin, et al.
Publicado: (2017)

Post-Transcriptional Dysregulation of microRNA and Alternative Polyadenylation in Colorectal Cancer
por: Mao, Zhanrui, et al.
Publicado: (2020)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

Prediction of potential small molecule−miRNA associations based on heterogeneous network representation learning
por: Li, Jianwei, et al.
Publicado: (2022)

Profiling Alternative 3′ Untranslated Regions in Sorghum using RNA-seq Data
por: Tu, Min, et al.
Publicado: (2020)

Mechanisms of Action of EGFR Tyrosine Kinase Receptor Incorporated in Extracellular Vesicles
por: Zanetti-Domingues, Laura C., et al.
Publicado: (2020)

Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer
por: Chang, Q, et al.
Publicado: (2008)

Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities
por: Mishani, Eyal, et al.
Publicado: (2008)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
por: Suda, Kenichi, et al.
Publicado: (2021)

From Science to Success? Targeting Tyrosine Kinase 2 in Spondyloarthritis and Related Chronic Inflammatory Diseases
por: Hromadová, Dominika, et al.
Publicado: (2021)

Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors
por: Amelia, Tasia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a1gp0306eisa1shdd09gea9muk